Recipharm invests in Analytical Development Services

Recipharm has today announced a significant strategic investment to expand capacity in analytical services and stability studies at its facility in Solna, Sweden.

The facility is equipped   with advanced laboratories and technology for pharmaceutical formulation as well as a GMP suite for development and manufacturing of sterile and non-sterile clinical trial materials.
It will now be reconstructed to facilitate expansion of analytical development within the Recipharm group. "This is a very important step for us as increasing this capacity will enable the company  to enhance the high quality  services to our  customers", says Maria Lundberg, General Manager at Recipharm Pharmaceutical Development. "Our analytical development service is already an integrated and vital part of the pharmaceutical development work, and this investment will enable our business to continue to grow, creating more flexibility and a better service offering. We are convinced that it is vital to small and large Pharma companies that competent service partners can supply high quality pharmaceutical development services including high quality analytical development.

Analytical services normally  included in the pharmaceutical offering  comprise: development and validation of stability indicating analytical methods, supply and execution of method transfer protocols, establishment of new product assay and degradation methods, graduated validation plans to suit the phase of drug development, cleaning validation, report writing and of course stability studies according to ICH. This expansion will mean that Recipharm will have the capability  to support more projects in parallel with these services.

The analytical lab in Solna will be ready and fully compliant with ICH, EU and FDA GMP in May 2013.

Notes to editors
About Recipharm
Recipharm AB is a leading contract development and manufacturing organisation
(CDMO) based in Sweden employing some 1,700 employees. The Company
operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms that include solid dose, granulates and powders, sterile liquids and lyophilisates, semi solids, beta-lactams, hormones, oral liquids, sprays and dry powder inhalers.
Recipharm's Pharmaceutical Development Services group offer services from straight forward manufacture of clinical trial material through to more complex product development and formulation. From our pharmaceutical development centre we can work on a variety of technologies, including sterile products. Formulation development, analytical method development and stability studies are all core activities.
For more information visit; www.recipharm.com

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.